Benjamin Morgan Scirica MD
Senior Physician and Director, Innovation, Cardiovascular Division, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, MassachusettsDr. Benjamin Scirica is a senior physician and Director of Innovation in the Cardiovascular Division at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. He is a Senior Investigator at the TIMI Study Group (an academic research organization based at Brigham and Women's Hospital that has performed over 75 clinical trials in cardiometabolic diseases).
His research interests center on the risk stratification, management, and the identifation of novel therapies to improve outcomes in patients with acute coronary syndromes and cardiometabolic disorders.
Dr. Scirica has authored or co-authored over 200 peer-reviewed articles and is a reviewer for multiple journals, including The New England Journal of Medicine, JAMA, The Lancet, Circulation, and Journal of the American College of Cardiology (JACC).
Disclosures
- Institutional research support to Brigham and Women’s Hospital from: Amgen; Better Therapeutics; Boehringer Ingelheim; Merck; Novo Nordisk; Pfizer; Verve Therapeutics
- Consulting fees from: AbbVie (DSMB); Amgen; AstraZeneca (DSMB); Bayer; Boehringer Ingelheim (DSMB); Elsevier Practice Update Cardiology; Hanmi (DSMB); Lexeo (DSMB); Novo Nordisk; Verve Therapeutics; and equity in Health [at] Scale; Arboretum Lifescience
Recent Contributions to PracticeUpdate:
- Chronic Inflammatory Disorders and Risk for T2DM, CHD, and Stroke
- High-Sensitivity vs Conventional Troponin in Patients With Acute Chest Pain
- Metformin Plus Insulin vs Sulfonylureas and Relation to CV Events and Death
- Significance of Worst Lead ST-Segment Elevation After STEMI
- Dabigatran Etexilate Associated With Increased Risk for Myocardial Infarction
- Delayed Filling of Clopidogrel Prescription After Coronary Stenting Increases Risk of Death and MI
- Non-STEMI and Nonobstructive CAD Linked to 1-Year Mortality
- Efficacy of a Cardiac Output–Guided Hemodynamic Therapy Algorithm on Outcome After Major GI Surgery
- Evolocumab Plus Moderate- or High-Intensity Statin Therapy Lowers LDL-C
- Dyslipidemia